These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

665 related items for PubMed ID: 12783592

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Imatinib mesylate.
    Waller CF.
    Recent Results Cancer Res; 2010; 184():3-20. PubMed ID: 20072827
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Imatinib mesylate in the treatment of chronic myelogenous leukemia.
    Borthakur G, Cortes JE.
    Int J Hematol; 2004 Jun; 79(5):411-9. PubMed ID: 15239390
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia.
    Manley PW, Cowan-Jacob SW, Mestan J.
    Biochim Biophys Acta; 2005 Dec 30; 1754(1-2):3-13. PubMed ID: 16172030
    [Abstract] [Full Text] [Related]

  • 32. Indications for imatinib mesylate therapy and clinical management.
    Guilhot F.
    Oncologist; 2004 Dec 30; 9(3):271-81. PubMed ID: 15169982
    [Abstract] [Full Text] [Related]

  • 33. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC, Zheng D, Li QH, Li XH, Cai CC, Luo SK, Li J, Peng AH, Tong XZ, Tan EX, Hong WD.
    Ai Zheng; 2004 Dec 30; 23(12):1696-9. PubMed ID: 15601563
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Imatinib.
    Lyseng-Williamson K, Jarvis B.
    Drugs; 2001 Dec 30; 61(12):1765-74; discussion 1775-6. PubMed ID: 11693465
    [Abstract] [Full Text] [Related]

  • 38. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
    Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE.
    Br J Haematol; 2002 Sep 30; 118(3):771-7. PubMed ID: 12181044
    [Abstract] [Full Text] [Related]

  • 39. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C, Sattler M.
    Crit Rev Oncol Hematol; 2006 Feb 30; 57(2):145-64. PubMed ID: 16213151
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.